Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition

Abstract Basal-like breast cancers (BLBC) are aggressive breast cancers that respond poorly to targeted therapies and chemotherapies. In order to define therapeutically targetable subsets of BLBC we examined two markers: cyclin E1 and BRCA1 loss. In high grade serous ovarian cancer (HGSOC) these mar...

Full description

Bibliographic Details
Main Authors: Diar Aziz, Neil Portman, Kristine J. Fernandez, Christine Lee, Sarah Alexandrou, Alba Llop-Guevara, Zoe Phan, Aliza Yong, Ashleigh Wilkinson, C. Marcelo Sergio, Danielle Ferraro, Dariush Etemadmoghadam, David D. Bowtell, kConFab Investigators, Violeta Serra, Paul Waring, Elgene Lim, C. Elizabeth Caldon
Format: Article
Language:English
Published: Nature Publishing Group 2021-08-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-021-00312-x

Internet

https://doi.org/10.1038/s41523-021-00312-x

Similar Items